About us

The Brody lab focuses on many molecular aspects of pancreatic cancer, including developing ways to target a novel pro-survival network in pancreatic cancer cells and optimizing current targeted therapies used in the clinic (i.e., an interest in personalizing therapy for pancreatic cancer patients, PanCAN, RAN grant PI).  Specifically, his lab is focused on an RNA binding protein, HuR, that is a involved in regulating a pro-survival network in various microenvironment settings involved with pancreatic cancer and targeting the DNA repair pathway (i.e., BRCAness) in pancreatic cancer. We study these and other pathways using different cutting-edged models of cancer (i.e., xenograft, orthotopic and genetically engineered mouse models; in vitro cell culture, CRISPR, siRNAs, etc).